Ypsomed and CamDiab today announced the launch of the mylife CamAPS FX app for automated insulin delivery on iOS platforms.

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

A year to the day after declaring the FDA’s clearance of its automated insulin pump, Sequel Med Tech announced that its first connected continuous glucose monitor will be Abbott’s FreeSty | Greenlit ...

We are thrilled to announce our collaboration with Abbott, integrating its world-leading FreeStyle Libre technology 2 as our first CGM partner, marking a significant milestone as we bring our ...

Sequel Med Tech announced today that it integrated its twiist automated insulin delivery (AID) with the Abbott FreeStyle Libre 3 Plus sensor.

"We are excited to welcome Alyson Trust to the Producto team,” said Mark Rauenzahn, CEO of Producto. "Her extensive experience in financial strategy, operational efficiency, and risk management will ...

Insulet (PODD) announced its revolutionary Omnipod 5 Automated Insulin Delivery System is now available in Australia and will soon be offered ...

Abbott Laboratories has experienced a 12.7% rise in stock price over the past year, outperforming the industry’s 9% growth.

In most cases, Abbott is one of three or four competitors that dominate the market, including nutrition, cardiac rhythm management devices, surgical heart valves, continuous glucose monitors, coronary ...

Abbott Laboratories ABT has witnessed strong momentum in the past year. Shares of the company have risen 12.7% compared with the 9% growth of the industry during the same time frame. The S&P 500 ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...